Armodafinil is a prescription wakefulness drug that will not cure sleep disorders

Armodafinil is a prescription wakefulness drug that will not cure sleep disorders
Image: Intellect (generated)

In short: Armodafinil is a prescription tablet that reduces daytime sleepiness in people with narcolepsy, shift work sleep disorder and sleep apnea. It is not a cure, and it is not a replacement for enough sleep. Its mechanism is still not fully understood, which makes it an interesting case of medicine that works before its full story is known.

Armodafinil belongs to a class of medicines called wakefulness-promoting agents. It is taken by mouth, usually once a day, and timed to the person's schedule: in the morning for narcolepsy or sleep apnea, and about an hour before a shift starts for shift work sleep disorder. Patients are told to take it at about the same time each day and to keep using any breathing devices or other treatments prescribed for sleep apnea. The drug reduces sleepiness but does not treat the underlying disorder. Because it can be habit forming, it should never be taken in a larger dose, more often, or for longer than a doctor prescribes. People are also warned that it may affect judgment, thinking and movement, so driving or operating machinery should wait until they know how it affects them, and alcohol should be avoided.

The way armodafinil works is not fully known. Research suggests it binds to the dopamine transporter and slows the reuptake of dopamine, a chemical messenger, and that this increases dopamine levels in the brain. Experiments in genetically modified mice without the transporter found that the related drug modafinil lost its wake-promoting effect, which points to this pathway, though other mechanisms may also contribute. The drug is also used beyond its approved uses, and the evidence there is weaker. Some studies suggest it may help as an add-on treatment for depression in bipolar disorder, but the effects were small and the quality of the evidence was considered low. Its use for attention deficit disorder is described as off-label and not a mainline treatment. Patients should discuss any use with their doctor.

theme_placeholder

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/health-armodafinil.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…